As medical professionals, we understand the impact quality research can have on how we care for our patients. The extensive adoption of electronic health records (EHRs) has enabled the collection of big data in rheumatology. This has provided a new and unique opportunity for the rheumatology community to conduct in-depth research into how patients are…
(Reuters Health)—Oral glucosamine has no more effect than placebo on joint pain, according to a new meta-analysis. The analysis of randomized controlled trials from which data have been made public found that at both three-month and 24-month follow-up points, the supplement had no effect on either hip or knee pain from arthritis. Even sub-groups, such…
BEDMINSTER, N.J. (Reuters)—U.S. President Donald Trump on Thursday declared the opioid epidemic a national emergency and said his administration was drafting papers to make it official. “The opioid crisis is an emergency and I’m saying officially right now it is an emergency,” Trump told reporters in New Jersey. “We’re going to draw it up and…
NEW YORK (Reuters Health)—Ultrasonography of the major salivary glands may have a role in the diagnostic evaluation of patients with clinically suspected primary Sjogren’s syndrome, researchers from the Netherlands report. Salivary gland biopsies and anti-SSA/Ro antibodies are important for classifying patients as primary Sjogren’s syndrome (pSS). Some studies have also supported using ultrasonography of the…
(Reuters)—New Hampshire sued OxyContin maker Purdue Pharma LP on Tuesday, joining several state and local governments in accusing the drugmaker of engaging in deceptive marketing practices that have helped fuel a national opioid addiction epidemic. The lawsuit filed in Merrimack County Superior Court claimed that Purdue Pharma significantly downplayed the risk of addiction posed by…
(Reuters)—The U.S. Drug Enforcement Administration (DEA) on Friday proposed a 20% reduction in the manufacture of certain commonly prescribed opioid painkillers, as well as other controlled substances for next year. The proposal comes as U.S. regulators and lawmakers take steps to limit the supply of opioids—a class of drugs that include prescription painkillers and heroin—to…
NEW YORK (Reuters Health)—The investigational drug romosozumab led to gains in hip bone mineral density (BMD) that were not seen with teriparatide in older women with osteoporosis transitioning from bisphosphonate therapy in the STRUCTURE study. Amgen’s romosozumab is a monoclonal antibody that inhibits sclerosin, a negative regulator of bone formation. In addition to stimulating bone…
An international task force has updated recommendations for axial and peripheral spondyloarthritis, and psoriatic arthritis, which include treat-to-target recommendations…
A systematic review has found that anti-tumor necrosis factor alpha treatment may improve endothelial function in RA patients. Despite the heterogeneity of the included studies, a random-effects model showed a significant improvement in endothelial function in this patient population after receiving infliximab, adalimumab or etanercept…
Continually building awareness and understanding of rheumatic diseases is critical to both our profession and patient care, according to Kelly Weselman, MD, a rheumatologist in Smyrna, Ga., and a passionate advocate involved in planning the ACR’s annual Rheumatic Disease Awareness Month (RDAM). “Unlike cancer patients, whose disease is well known, patients battling a rheumatic disease…